Laboratory biomarker predictors for disease progression and outcome among Egyptian COVID-19 patients

Fathalla, Lamiaa A.; Kamal, Lamyaa Mohamed; Salaheldin, Omina; Khalil, Mahmoud A F; Kamel, Mahmoud M.; Fahim, Hagar H; Abdel-Moneim, Youssef A. S.; Abdulhakim, Jawaher A; Abdel‐Moneim, Ahmed S.; El-Meligui, Yomna M

doi:10.1177/03946320221096207

Cited by 5 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lactate dehydrogenase plays a vital role in biochemical processes; it takes part in the inter-conversion of pyruvate, the final product of glycolysis to lactate without sufficient oxygen supply [ 29 , 30 ]. Elevated LDH activity indicates a lack or deficiency of oxygen in biochemical processes, tissue oxygen deficiency, or multi-organ failure [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis

Fialek

Pruc²,

Smereka

et al. 2022

Cardiol J.

View full text Add to dashboard Cite

Background: This meta-analysis outlines the role of elevated lactate dehydrogenase (LDH) levels in assessing the severity of coronavirus disease 2019 . Methods: The current study was designed as a systematic review and meta-analysis. Embase, Pub-Med, Web of Science, Scopus and Cochrane Central Register of Controlled Trials were searched to identify the usefulness of LDH as a marker of COVID-19 severity. All extracted data were analyzed using RevMan V.5.4 or STATA V.14 software. Results: A total of 264 records were selected for this meta-analysis. Pooled analysis showed that LDH levels were statistically significantly lower in the group of survivors compared to patients who died in hospital (standardized mean differences [SMD] = -3.10; 95% confidence interval [CI]: -3.40 to -2.79; I 2 = 99%; p < 0.001). Lower LDH levels were observed in non-severe groups compared to severe course of ; I 2 = 99%; p < 0.001). The level of LDH was statistically significantly lower in the severe group compared to the critical group (SMD = -1.48; 95% CI: -2.04 to -0.92; I 2 = 98%; p < 0.001). Patients who did not require treatment in the intensive care unit (ICU) showed significantly lower levels of LDH compared to patients who required treatment in the ICU (SMD = -3.78; 95% CI: -4.48 to -3.08; I 2 = 100%; p < 0.001). Conclusions: This meta-analysis showed that elevated LDH was associated with a poor outcome in

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis

Fialek

Pruc²,

Smereka

et al. 2022

Cardiol J.

View full text Add to dashboard Cite

show abstract

“…Although previous observational studies have reported several other inflammatory or coagulation-related makers for the prediction of prognostic outcomes in patients contracting COVID-19 [ 49 , 50 ], our meta-analysis is the first to investigate the association of the F/A ratio with poor prognosis. A previous meta-analysis involving more than two thousand patients revealed significantly higher CRP levels among those who succumbed to COVID-19 than in survivors [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Association between Fibrinogen-to-Albumin Ratio and Prognosis of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Although the fibrinogen-to-albumin ratio (F/R ratio) has been used as an inflammation marker to predict clinical outcomes in patients with cardiovascular diseases, its association with the prognosis of patients with coronavirus disease 2019 (COVID-19) remains unclear. Electronic databases including EMBASE, MEDLINE, Google Scholar, and Cochrane Library were searched from inception to 20 June 2022. The associations of F/R ratio with poor prognosis (defined as the occurrence of mortality or severe disease) were investigated in patients with COVID-19. A total of 10 studies (seven from Turkey, two from China, one from Croatia) involving 3675 patients published between 2020 and 2022 were eligible for quantitative syntheses. Merged results revealed a higher F/R ratio in the poor prognosis group (standardized mean difference: 0.529, p < 0.001, I2 = 84.8%, eight studies) than that in the good prognosis group. In addition, a high F/R ratio was associated with an increased risk of poor prognosis (odds ratio: 2.684, I2 = 59.5%, five studies). Pooled analysis showed a sensitivity of 0.75, specificity of 0.66, and area under curve of 0.77 for poor prognosis prediction. In conclusion, this meta-analysis revealed a positive correlation between F/A ratio and poor prognostic outcomes of COVID-19. Because of the limited number of studies included, further investigations are warranted to support our findings.

show abstract

“…Thus, patients with lower platelet-monocyte aggregates might have a higher risk of thrombosis and severe pneumonia. In addition, our results showed that other severity markers were associated with platelet-monocyte aggregates, including lymphocyte count [31], lactate dehydrogenase, and IL-6 [32].…”

Section: Discussionmentioning

confidence: 53%

Increased platelet activation and lower platelet-monocyte aggregates in COVID-19 patients with severe pneumonia

Srihirun

Sriwantana²,

Srichatrapimuk³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background The increased procoagulant platelets and platelet activation are associated with thrombosis in COVID-19. In this study, we investigated platelet activation in COVID-19 patients and their association with other disease markers. Methods COVID-19 patients were classified into three severity groups: no pneumonia, mild-to-moderate pneumonia, and severe pneumonia. The expression of P-selectin and activated glycoprotein (aGP) IIb/IIIa on the platelet surface and platelet-leukocyte aggregates were measured prospectively on admission days 1, 7, and 10 by flow cytometry. Results P-selectin expression, platelet-neutrophil, platelet-lymphocyte, and platelet-monocyte aggregates were higher in COVID-19 patients than in uninfected control individuals. In contrast, aGPIIb/IIIa expression was not different between patients and controls. Severe pneumonia patients had lower platelet-monocyte aggregates than patients without pneumonia and patients with mild-to-moderate pneumonia. Platelet-neutrophil and platelet-lymphocyte aggregates were not different among groups. There was no change in platelet-leukocyte aggregates and P-selectin expression on days 1, 7, and 10. aGPIIb/IIIa expression was not different among patient groups. Still, adenosine diphosphate (ADP)-induced aGPIIb/IIIa expression was lower in severe pneumonia than in patients without and with mild-to-moderate pneumonia. Platelet-monocyte aggregates exhibited a weak positive correlation with lymphocyte count and weak negative correlations with interleukin-6, D-dimer, lactate dehydrogenase, and nitrite. Conclusion COVID-19 patients have higher platelet-leukocyte aggregates and P-selectin expression than controls, indicating increased platelet activation. Compared within patient groups, platelet-monocyte aggregates were lower in severe pneumonia patients.

show abstract

Laboratory biomarker predictors for disease progression and outcome among Egyptian COVID-19 patients

Cited by 5 publications

References 36 publications

Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis

Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis

Association between Fibrinogen-to-Albumin Ratio and Prognosis of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis

Increased platelet activation and lower platelet-monocyte aggregates in COVID-19 patients with severe pneumonia

Contact Info

Product

Resources

About